DUBLIN, Apr. 25, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Pancreatic Cancer Treatment Market Analysis By Affected Region (Exocrine, Endocrine), By Type (Chemotherapy, Targeted Therapy, Others), By Region (North America, Europe, Asia Pacific, Latin America And MEA), And Segment Forecasts, 2014 - 2025" report to their offering.
The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025
Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period.
According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.
Further key findings from the study suggest:
- The study suggests that exocrine cancer is by far the most common type of pancreatic cancer accounting for more than 95% of the overall pancreatic cancer types
- Among the treatment types, targeted therapy occupied the largest share since it is considered as the most effective treatment option, which blocks the growth and spread of cancer cells without damaging healthy cells
- North America dominated the segment with the largest revenue share in 2015 due to high adoption rate of advanced treatment options and highly developed healthcare infrastructure
- Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to increasing government initiatives, growing awareness regarding the treatment options for pancreatic cancer, and the availability of highly sophisticated medical infrastructure for effective treatment
- Some of the major companies operating in this market are, but are not limited to, Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.
Key Topics Covered:
1 Research Methodology
2 Executive Summary
2.1 Market Snapshot
3 Pancreatic Cancer Treatment Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Market Size and Growth Prospects
3.2.1 Market driver analysis
3.2.2 Market restraint analysis
3.3 Key Opportunities Prioritized
3.4 Industry Analysis Porter's
3.5 PESTEL Analysis
4 Pancreatic Cancer Treatment Market: Affected Region Estimates & Trend Analysis
4.1 Pancreatic Cancer Treatment Market: Affected Region Movement Analysis
5 Pancreatic Cancer Treatment Market: Treatment Estimates & Trend Analysis
5.1 Pancreatic Cancer Treatment Market: Treatment Movement Analysis
5.3 Targeted Therapy
6 Pancreatic Cancer Treatment Market: Regional Estimates & Trend Analysis, by Affected region & Application
7 Competitive Landscape
- Eli Lily and Company
- Celgene Corporation
- Hoffmann-La Roche AG
- Amgen, Inc.
- Novartis AG
- PharmaCyte Biotech, Inc.
- Clovis Oncology
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Pfizer, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/qcjstr/pancreatic_cancer
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-42-billion-pancreatic-cancer-treatment-chemotherapy-targeted-therapy-others-market-analysis-2014-2047--2025---research-and-markets-300444324.html
SOURCE Research and Markets